INTRODUCTION: The purpose of this study was to evaluate the utility of magnetic resonance digital subtraction angiography (MRDSA) in showing the presence or absence of retrograde venous drainage (RVD) in patients with intracranial dural arteriovenous fistula (DAVF) involving the transverse sigmoid sinus (TSS) after treatment. METHODS: Of 16 patients with DAVF involving the TSS, 13 underwent digital subtraction angiography (DSA) and MRDSA before and after treatment, and 3 underwent DSA before treatment and DSA and MRDSA after treatment. Five patients underwent these procedures twice after treatment. A total of 21 examinations after treatment were evaluated retrospectively. The presence or absence of DAVF and RVD was decided on the basis of the DSA findings. Two neuroradiologists reviewed the MRDSA findings concerning the presence or absence of DAVF and RVD. RESULTS: DSA showed residual DAVF in 9 and residual RVD in 5 of 21 examinations. MRDSA revealed residual DAVF in 8 of 21 examinations. MRDSA did not show residual DAVF in one examination because of a very small (low-flow) residual DAVF without RVD. MRDSA identified residual RVD in 5 of 21 examinations. MRDSA was completely consistent with DSA concerning the presence or absence of residual RVD. CONCLUSION: MRDSA could evaluate the presence or absence of RVD in patients with DAVF involving TSS after treatment. MRDSA may give reliable information as to whether patients with DAVF involving the TSS should undergo additional DSA after treatment.
INTRODUCTION: The purpose of this study was to evaluate the utility of magnetic resonance digital subtraction angiography (MRDSA) in showing the presence or absence of retrograde venous drainage (RVD) in patients with intracranial dural arteriovenous fistula (DAVF) involving the transverse sigmoid sinus (TSS) after treatment. METHODS: Of 16 patients with DAVF involving the TSS, 13 underwent digital subtraction angiography (DSA) and MRDSA before and after treatment, and 3 underwent DSA before treatment and DSA and MRDSA after treatment. Five patients underwent these procedures twice after treatment. A total of 21 examinations after treatment were evaluated retrospectively. The presence or absence of DAVF and RVD was decided on the basis of the DSA findings. Two neuroradiologists reviewed the MRDSA findings concerning the presence or absence of DAVF and RVD. RESULTS: DSA showed residual DAVF in 9 and residual RVD in 5 of 21 examinations. MRDSA revealed residual DAVF in 8 of 21 examinations. MRDSA did not show residual DAVF in one examination because of a very small (low-flow) residual DAVF without RVD. MRDSA identified residual RVD in 5 of 21 examinations. MRDSA was completely consistent with DSA concerning the presence or absence of residual RVD. CONCLUSION: MRDSA could evaluate the presence or absence of RVD in patients with DAVF involving TSS after treatment. MRDSA may give reliable information as to whether patients with DAVF involving the TSS should undergo additional DSA after treatment.
Authors: S G Wetzel; D Bilecen; P Lyrer; G Bongartz; E Seifritz; E W Radue; K Scheffler Journal: AJR Am J Roentgenol Date: 2000-05 Impact factor: 3.959
Authors: S Aoki; T Yoshikawa; M Hori; A Nanbu; H Kumagai; Y Nishiyama; H Nukui; T Araki Journal: AJR Am J Roentgenol Date: 2000-08 Impact factor: 3.959
Authors: Junichiro Satomi; J Marc C van Dijk; Karel G Terbrugge; Robert A Willinsky; M Christopher Wallace Journal: J Neurosurg Date: 2002-10 Impact factor: 5.115
Authors: T A Cashen; J C Carr; W Shin; M T Walker; S F Futterer; A Shaibani; R M McCarthy; T J Carroll Journal: AJNR Am J Neuroradiol Date: 2006-04 Impact factor: 3.825
Authors: C Cognard; Y P Gobin; L Pierot; A L Bailly; E Houdart; A Casasco; J Chiras; J J Merland Journal: Radiology Date: 1995-03 Impact factor: 11.105
Authors: K Noguchi; N Kuwayama; M Kubo; Y Kamisaki; K Kameda; G Tomizawa; H Kawabe; H Seto Journal: AJNR Am J Neuroradiol Date: 2010-09-02 Impact factor: 3.825
Authors: Andrea Bink; Joachim Berkefeld; Marlies Wagner; Se-Jong You; Hanns Ackermann; Matthias W Lorenz; Christian Senft; Richard du Mesnil de Rochemont Journal: Eur Radiol Date: 2011-09-21 Impact factor: 5.315